Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

 

Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial

Cegolon et al., Pharmaceutics, doi:10.3390/pharmaceutics14112502, RENAISSANCE, NCT05458336
Nov 2022  
  Post
  Facebook
Share
  Source   PDF  
Viral clearance, mid-reco.. 32% Improvement Relative Risk Viral clearance, day 2 2% Viral clearance, day 3 8% Viral clearance, day 4 18% Viral clearance, day 5 24% Viral clearance, day 6 26% Viral clearance, day 7 32% Viral clearance, day 8 31% Viral clearance, day 9 67% Viral clearance, day 10 77% Viral clearance, day 11 86% Xylitol for COVID-19  RENAISSANCE  LATE TREATMENT Is late treatment with xylitol beneficial for COVID-19? Prospective study of 108 patients in Italy (February - March 2022) Improved viral clearance with xylitol (not stat. sig., p=0.053) c19early.org Cegolon et al., Pharmaceutics, November 2022 Favorsxylitol Favorscontrol 0 0.5 1 1.5 2+
108 patient prospective study showing improved viral clearance with Panthexyl nasal spray (a sterile hypertonic solution containing seawater, xylitol, panthenol and lactic acid).
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects (early treatment may be more beneficial).
risk of no viral clearance, 32.3% lower, RR 0.68, p = 0.05, treatment 21 of 50 (42.0%), control 36 of 58 (62.1%), NNT 5.0, mid-recovery, day 7.
risk of no viral clearance, 2.0% lower, RR 0.98, p = 0.46, treatment 49 of 50 (98.0%), control 58 of 58 (100.0%), NNT 50, day 2.
risk of no viral clearance, 8.0% lower, RR 0.92, p = 0.04, treatment 46 of 50 (92.0%), control 58 of 58 (100.0%), NNT 13, day 3.
risk of no viral clearance, 18.0% lower, RR 0.82, p < 0.001, treatment 41 of 50 (82.0%), control 58 of 58 (100.0%), NNT 5.6, day 4.
risk of no viral clearance, 24.1% lower, RR 0.76, p = 0.001, treatment 36 of 50 (72.0%), control 55 of 58 (94.8%), NNT 4.4, day 5.
risk of no viral clearance, 26.4% lower, RR 0.74, p = 0.004, treatment 33 of 50 (66.0%), control 52 of 58 (89.7%), NNT 4.2, day 6.
risk of no viral clearance, 32.3% lower, RR 0.68, p = 0.05, treatment 21 of 50 (42.0%), control 36 of 58 (62.1%), NNT 5.0, day 7.
risk of no viral clearance, 31.1% lower, RR 0.69, p = 0.08, treatment 19 of 50 (38.0%), control 32 of 58 (55.2%), NNT 5.8, day 8.
risk of no viral clearance, 66.9% lower, RR 0.33, p < 0.001, treatment 8 of 50 (16.0%), control 28 of 58 (48.3%), NNT 3.1, day 9.
risk of no viral clearance, 76.8% lower, RR 0.23, p = 0.008, treatment 3 of 50 (6.0%), control 15 of 58 (25.9%), NNT 5.0, day 10.
risk of no viral clearance, 85.5% lower, RR 0.15, p = 0.04, treatment 1 of 50 (2.0%), control 8 of 58 (13.8%), NNT 8.5, day 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cegolon et al., 18 Nov 2022, prospective, Italy, peer-reviewed, survey, 6 authors, study period 23 February, 2022 - 18 March, 2022, trial NCT05458336 (history) (RENAISSANCE). Contact: luca.cegolon@units.it (corresponding author), l.cegolon@gmail.com.
This PaperMiscellaneousAll
Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial
Luca Cegolon, Giuseppe Mastrangelo, Enzo Emanuelli, Riccardo Camerotto, Giacomo Spinato, Daniele Frezza
Pharmaceutics, doi:10.3390/pharmaceutics14112502
Background: COVID-19 is an asymptomatic condition in 40% of cases, and most symptomatic patients present with mild/moderate disease not requiring hospitalization or intensive care, especially during the Omicron wave, when the hospitalization rate was estimated to be 0.3%. The main port of entry for SARS-CoV-2 in the human body is the nasal cavity and the upper respiratory tract is affected since the early stages of the infection. Nasal irrigation or aerosol by isotonic or hypertonic saline solution is a traditional therapeutic approach for respiratory or nasal inflammation, also featured by prophylactic properties against upper respiratory infections. Methods: We conducted a prospective open-label controlled study to assess the superiority of an already existing medication (Tonimer Lab Panthexyl 800)-a sterile hypertonic solution containing seawater, xylitol, panthenol and lactic acid-to reduce the viral shedding time in patients affected by asymptomatic or mild COVID-19. COVID-19 patients (N = 108) were split into two groups: a treatment arm (50 participants receiving standard of care plus nasal spray 3 times/day with Tonimer Lab Panthexyl 800) and a control arm (58 participants receiving standard of care but nasal spray with Tonimer Lab Panthexyl 800). The two groups, both testing initially positive for SARS-CoV-2 at real-time PCR (RT-PCR) on nasal swab, were followed up over time to assess the daily number of positive swab tests turning negative (study endpoint). Treatment effectiveness at various time lags since the first positive RT-PCR swab test was measured by rate of events in the experimental arm (EER) and in the control arm (CER), absolute risk increase (ARI) = (EER -CER), and number needed to treat (NNT) = (1/ARI). To investigate the endpoint, we used logistic and Cox regression models, expressing the result as odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (95%CI), respectively. The symptoms recorded with a modified COVID-Q questionnaire at both diagnosis and first negative antigenic swab test were compared in each group (treated versus controls) by exact symmetry test. Results: During the first five days of treatment, COVID-19 patients treated with Tonimer Lab Panthexyl 800 were more likely to become negative two days before controls. According to NNT, four subjects had to be treated for five days to achieve the study endpoint in one individual. The negativization rate in patients treated with Tonimer Lab Panthexyl 800 was significantly higher than patients' treated with standard of care alone (OR = 7.39, 95%CI: 1.83-29.8; HR = 6.12, 95%CI: 1.76-21.32). There was no evidence of side effects. Conclusions: Nasal spray with Tonimer Lab Panthexyl 800 was effective against SARS-CoV-2, stopping viral shedding in the treatment arm two days before the control group. This treatment should be continued for at least five days after the first positive swab test for SARS-CoV-2.
Penicillin intake No Furthermore, apart from a few symptoms improving more in controls (productive cough, stuffy nose, runny nose, breath shortage, anosmia/ageusia), most conditions (ear wadding, dry cough, lacrimation, feverish sensation, sweating, shivering, headache, sore Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Conflicts of Interest: The authors declare no conflict of interest.
References
Akgun, Tuzuner, Sahin, Kilercik, Kulah et al., Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients, doi:10.1371/journal.pone.0240012
Ashby, Inorganic chemistry of defensive peroxidases in the human oral cavity, J. Dent. Res, doi:10.1177/154405910808701003
Cegolon, Investigating hypothiocyanite against SARS-CoV-2, Int. J. Hyg. Environ. Health, doi:10.1016/j.ijheh.2020.113520
Cegolon, Javanbakht, Mastrangelo, Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents, Int. J. Hyg. Environ. Health, doi:10.1016/j.ijheh.2020.113605
Cegolon, Mirandola, Salaris, Salvati, Mastrangelo et al., Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2. Pathogens 2021, doi:10.3390/pathogens10020233
Cegolon, Ronchese, Ricci, Negro, Larese-Filon, Occupational Risk and the Impact of the Omicron Variant, Viruses
Chatterjee, Chakraborty, Naskar, Saha, Bandyapadhyay et al., Efficacy of Normal Saline Nasal Spray and Gargle on SARS-CoV-2 for Prevention of COVID-19 Pneumonia
Ciprandi, La, Brunese, Varricchio, Varricchio, Hypertonic saline with xylitol and hyaluronate may shorten the viral shedding duration in asymptomatic COVID-19 positive subjects: A pilot study, J. Biol. Regul. Homeost. Agents
Farrell, Klatt-Cromwell, Schneider, Benefits and safety of nasal saline irrigations in a pandemic-Washing COVID-19 away, JAMA Otolaryngol.-Head Neck Surg, doi:10.1001/jamaoto.2020.1622
Fisher, Dixon, Herson, Frankowski, Hearron et al., Intention to treat in clinical trials
Georgiou, Alevizopoulos, Nasal Irrigation in the COVID-19 Era, IJCMCR
Giarratana, Rajan, Kamala, Mendenhall, Reiner, A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: A new potential solution for upper respiratory tract hygiene, Arch. Otorhinolaryngol, doi:10.1007/s00405-021-06644-5
Hui, Yii, Robinson, Xylitol nasal preparations in sinonasal disease: A literature review and meta-analysis, Aust. J. Otolaryngol, doi:10.21037/ajo-21-45
Huijghebaert, Hoste, Vanham, Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19, Eur. J. Clin. Pharmacol, doi:10.1007/s00228-021-03102-3
Jin, Yang, Ji, Wu, Chen et al., Virology, epidemiology, pathogenesis, and control of COVID-19, Viruses, doi:10.3390/v12040372
Kanjanawasee, Seresirikachorn, Chitsuthipakorn, Snidvongs, Hypertonic saline versus isotonic saline nasal irrigation: Systematic review and meta-analysis, Am. J. Rhinol. Allergy, doi:10.1177/1945892418773566
Kasahara, Kawakami, Kiyono, Yonemura, Kawamura et al., Ubiquitinproteasome system controls ciliogenesis at the initial step of axoneme extension, Nat. Commun, doi:10.1038/ncomms6081
Kimura, Freeman, Wessinger, Gupta, Sheng et al., Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with COVID-19, Int. Forum Allergy Rhinol, doi:10.1002/alr.22703
Lamers, Haagmans, SARS-CoV-2 pathogenesis, Nat. Rev. Microbiol, doi:10.1038/s41579-022-00713-0
Liu, Yan, Wan, Xiang, Le et al., Viral dynamics in mild and severe cases of COVID-19, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30232-2
Machado, Glaser, Araujo, Petiz, Oliveira et al., Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells, ACS Pharmacol. Trans. Sci, doi:10.1021/acsptsci.1c00080
Mao, Wang, Ma, Wu, Sun, Reinfection rates among patients previously infected by SARS-CoV-2: Systematic review and meta-analysis, Chin. Med. J, doi:10.1097/CM9.0000000000001892
Masood, Moumoulidis, Panesar, Acute rhinosinusitis in adults: An update on current management, Postgrad. Med. J, doi:10.1136/pgmj.2006.054767
Meister, Todt, Brüggemann, Steinmann, Banava et al., Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2, J. Hosp. Infect. 2022, doi:10.1016/j.jhin.2021.10.019
Nagl, Arnitz, Lackner, N-chlorotaurine, a promising future candidate for topical therapy of fungal infections, Mycopathologia, doi:10.1007/s11046-017-0175-z
Nct05458336, A Non-Randomized Controlled Clinical Trial on the Use of Saline Nasal Irrigations to Eradicate Localized Nasal Infection by SARS-CoV-2
Proksch, De Bony, Trapp, Boudon, Topical use of dexpanthenol: A 70th anniversary article, J. Dermatol. Treat, doi:10.1080/09546634.2017.1325310
Ramalingam, Graham, Dove, Morrice, Sheikh, A pilot, open labelled, randomized con-trolled trial of hypertonic saline nasal irrigation and gargling for the common cold, Sci. Rep, doi:10.1038/s41598-018-37703-3
Ramalingam, Graham, Dove, Morrice, Sheikh, Hypertonic saline nasal irrigation and gar-gling should be considered as a treatment option for COVID-19, J. Glob. Health, doi:10.7189/jogh.10.010332
Rosati, Giordano, Concato, Hypertonic saline nasal irrigation and gargling as an inexpensive practical adjunctive weapon to combat asymptomatic SARS-CoV-2 infections. A case reports, Trends Med, doi:10.15761/TiM.1000249
Smale, Differentiable dynamical systems, Bull. Am. Math. Soc, doi:10.1090/S0002-9904-1967-11798-1
Speir, Effect of several inorganic salts on the infectivity of Mengo virus, Proc. Soc. Exp. Biol. Med
Spinato, Fabbris, Conte, Menegaldo, Franz et al., COVID-Q: Validation of the first COVID-19 questionnaire based on patient-rated symptom gravity, Int. J. Clin, doi:10.1111/ijcp.14829
Tenovuo, Lehtonen, Aaltonen, Vilja, Tuohimaa, Antimicrobial factors in whole saliva of human infants, Infect. Immun, doi:10.1128/iai.51.1.49-53.1986
Varricchio, La, Brunese, Ciprandi, Smell recovery in patients with COVID-19: An experience with nebulized nasal treatment, J. Biol. Regul. Homeost. Agents
Varricchio, La, Brunese, Varricchio, Ciprandi, Viral shedding in symptomatic patients with mild COVID-19: An experience with nebulized nasal treatment, J. Biol. Regul. Homeost. Agents
Wennmacker, Van Dijk, Drenth, Donkervoort, Boerma et al., Statistical analysis plan of a randomized controlled trial to compare a restrictive strategy to usual care for the effectiveness of cholecystectomy (SECURE trial), Trials, doi:10.1186/s13063-018-2989-5
Yan, Zhang, Chen, Jiang, Liu et al., Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A systematic review and meta-analysis, Front. Public Health, doi:10.3389/fpubh.2021.652842
Yang, Teha, Lian, Suah, Husin et al., SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period, Lancet Reg. Health-Western Pac, doi:10.1016/j.lanwpc.2022.100572
Yildiz, Koca, Kuzu, Günebakan, Bucak et al., Comparison of the Healing Effect of Nasal Saline Irrigation with Triamcinolone Acetonide Versus Nasal Saline Irrigation alone in COVID-19 Related Olfactory Dysfunction: A Randomized Controlled Study, Indian J. Otolaryngol. Head Neck Surg, doi:10.1007/s12070-021-02749-9
Zou, Ruan, Huang, Liang, Huang et al., SARS-CoV-2 Viral load in upper respiratory specimens of infected patients, N. Engl. J. Med, doi:10.1056/NEJMc2001737
Štanfel, Kalogjera, Ryazantsev, Hlača, Radtsig et al., The role of seawater and saline solutions in treatment of upper respiratory conditions, Mar. Drugs, doi:10.3390/md20050330
DOI record: { "DOI": "10.3390/pharmaceutics14112502", "ISSN": [ "1999-4923" ], "URL": "http://dx.doi.org/10.3390/pharmaceutics14112502", "abstract": "<jats:p>Background: Non-hospitalized patients with asymptomatic or mild/moderate disease account for about 81% of COVID-19 patients, whose upper respiratory tract is affected since the early stages of the infection. Nasal irrigation or aerosol by isotonic or hypertonic saline solution is a traditional therapeutic approach for respiratory or nasal inflammation, also featured by prophylactic properties. Methods: We conducted a prospective open-label controlled study to assess the superiority of an already existing medication (Tonimer Lab Panthexyl 800)—a sterile hypertonic solution containing seawater, xylitol, panthenol and lactic acid—to reduce the viral shedding time in patients affected by asymptomatic or mild COVID-19. COVID-19 patients (N = 108) were split into two groups: a treatment arm (50 participants receiving standard of care plus nasal spray 3 times/day with Tonimer Lab Panthexyl 800) and a control arm (58 participants receiving standard of care but nasal spray with Tonimer Lab Panthexyl 800). The two groups, both testing initially positive for SARS-CoV-2 at real-time PCR (RT-PCR) on nasal swab, were followed up over time to assess the daily number of positive swab tests turning negative (study endpoint). Treatment effectiveness at various time lags since the first positive RT-PCR swab test was measured by rate of events in the experimental arm (EER) and in the control arm (CER), absolute risk increase (ARI) = (EER − CER), and number needed to treat (NNT) = (1/ARI). To investigate the endpoint, we used logistic and Cox regression models, expressing the result as odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (95%CI), respectively. The symptoms recorded with a modified COVID-Q questionnaire at both diagnosis and first negative antigenic swab test were compared in each group (treated versus controls) by exact symmetry test. Results: During the first five days of treatment, COVID-19 patients treated with Tonimer Lab Panthexyl 800 were more likely to become negative two days before controls. According to NNT, four subjects had to be treated for five days to achieve the study endpoint in one individual. The negativization rate in patients treated with Tonimer Lab Panthexyl 800 was significantly higher than patients’ treated with standard of care alone (OR = 7.39, 95%CI: 1.83–29.8; HR = 6.12, 95%CI: 1.76–21.32). There was no evidence of side effects. Conclusions: Nasal spray with Tonimer Lab Panthexyl 800 was effective against SARS-CoV-2, stopping viral shedding in the treatment arm two days before the control group. This treatment should be continued for at least five days after the first positive swab test for SARS-CoV-2.</jats:p>", "alternative-id": [ "pharmaceutics14112502" ], "author": [ { "affiliation": [], "family": "Cegolon", "given": "Luca", "sequence": "first" }, { "affiliation": [], "family": "Mastrangelo", "given": "Giuseppe", "sequence": "additional" }, { "affiliation": [], "family": "Emanuelli", "given": "Enzo", "sequence": "additional" }, { "affiliation": [], "family": "Camerotto", "given": "Riccardo", "sequence": "additional" }, { "affiliation": [], "family": "Spinato", "given": "Giacomo", "sequence": "additional" }, { "affiliation": [], "family": "Frezza", "given": "Daniele", "sequence": "additional" } ], "container-title": "Pharmaceutics", "container-title-short": "Pharmaceutics", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 11, 18 ] ], "date-time": "2022-11-18T08:57:44Z", "timestamp": 1668761864000 }, "deposited": { "date-parts": [ [ 2022, 11, 18 ] ], "date-time": "2022-11-18T09:27:11Z", "timestamp": 1668763631000 }, "indexed": { "date-parts": [ [ 2023, 8, 2 ] ], "date-time": "2023-08-02T17:53:02Z", "timestamp": 1690998782773 }, "is-referenced-by-count": 7, "issue": "11", "issued": { "date-parts": [ [ 2022, 11, 18 ] ] }, "journal-issue": { "issue": "11", "published-online": { "date-parts": [ [ 2022, 11 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 11, 18 ] ], "date-time": "2022-11-18T00:00:00Z", "timestamp": 1668729600000 } } ], "link": [ { "URL": "https://www.mdpi.com/1999-4923/14/11/2502/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "2502", "prefix": "10.3390", "published": { "date-parts": [ [ 2022, 11, 18 ] ] }, "published-online": { "date-parts": [ [ 2022, 11, 18 ] ] }, "publisher": "MDPI AG", "reference": [ { "key": "ref_1", "unstructured": "European Centre for Disease Prevention and Control (2022, October 04). Clinical Characteristics of COVID-19. Available online: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical." }, { "DOI": "10.1038/s41579-022-00713-0", "article-title": "SARS-CoV-2 pathogenesis", "doi-asserted-by": "crossref", "first-page": "270", "journal-title": "Nat. Rev. Microbiol.", "key": "ref_2", "volume": "20", "year": "2022" }, { "DOI": "10.1056/NEJMc2001737", "article-title": "SARS-CoV-2 Viral load in upper respiratory specimens of infected patients", "doi-asserted-by": "crossref", "first-page": "1177", "journal-title": "N. Engl. J. Med.", "key": "ref_3", "volume": "382", "year": "2020" }, { "DOI": "10.1097/CM9.0000000000001892", "article-title": "Reinfection rates among patients previously infected by SARS-CoV-2: Systematic review and meta-analysis", "doi-asserted-by": "crossref", "first-page": "145", "journal-title": "Chin. Med. J.", "key": "ref_4", "volume": "135", "year": "2022" }, { "DOI": "10.1016/j.lanwpc.2022.100572", "article-title": "SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period", "doi-asserted-by": "crossref", "first-page": "100572", "journal-title": "Lancet Reg. Health—Western Pac.", "key": "ref_5", "volume": "26", "year": "2022" }, { "DOI": "10.21203/rs.3.rs-153598/v2", "doi-asserted-by": "crossref", "key": "ref_6", "unstructured": "Chatterjee, U., Chakraborty, A., Naskar, S., Saha, B., Bandyapadhyay, B., and Shee, S. (2021). Efficacy of Normal Saline Nasal Spray and Gargle on SARS-CoV-2 for Prevention of COVID-19 Pneumonia, Research Square." }, { "DOI": "10.1016/j.ijheh.2020.113605", "article-title": "Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents", "doi-asserted-by": "crossref", "first-page": "113605", "journal-title": "Int. J. Hyg. Environ. Health", "key": "ref_7", "volume": "230", "year": "2020" }, { "DOI": "10.1016/j.ijheh.2020.113520", "article-title": "Investigating hypothiocyanite against SARS-CoV-2", "doi-asserted-by": "crossref", "first-page": "113520", "journal-title": "Int. J. Hyg. Environ. Health", "key": "ref_8", "volume": "227", "year": "2020" }, { "DOI": "10.3390/pathogens10020233", "doi-asserted-by": "crossref", "key": "ref_9", "unstructured": "Cegolon, L., Mirandola, M., Salaris, C., Salvati, M.V., Mastrangelo, G., and Salata, C. (2021). Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2. Pathogens, 10." }, { "DOI": "10.7189/jogh.10.010332", "article-title": "Hypertonic saline nasal irrigation and gar-gling should be considered as a treatment option for COVID-19", "doi-asserted-by": "crossref", "first-page": "010332", "journal-title": "J. Glob. Health", "key": "ref_10", "volume": "10", "year": "2020" }, { "DOI": "10.1038/s41598-018-37703-3", "article-title": "A pilot, open labelled, randomized con-trolled trial of hypertonic saline nasal irrigation and gargling for the common cold", "doi-asserted-by": "crossref", "first-page": "1015", "journal-title": "Sci. Rep.", "key": "ref_11", "volume": "9", "year": "2019" }, { "DOI": "10.1177/1945892418773566", "article-title": "Hypertonic saline versus isotonic saline nasal irrigation: Systematic review and meta-analysis", "doi-asserted-by": "crossref", "first-page": "269", "journal-title": "Am. J. Rhinol. Allergy", "key": "ref_12", "volume": "32", "year": "2018" }, { "DOI": "10.20944/preprints202202.0313.v3", "doi-asserted-by": "crossref", "key": "ref_13", "unstructured": "Štanfel, D., Kalogjera, L., Ryazantsev, S.V., Hlača, K., Radtsig, E.Y., Teimuraz, R., and Hrabač, P. (2022). The role of seawater and saline solutions in treatment of upper respiratory conditions. Mar. Drugs, 20." }, { "DOI": "10.1001/jamaoto.2020.1622", "article-title": "Benefits and safety of nasal saline irrigations in a pandemic—Washing COVID-19 away", "doi-asserted-by": "crossref", "first-page": "787", "journal-title": "JAMA Otolaryngol.–Head Neck Surg.", "key": "ref_14", "volume": "146", "year": "2020" }, { "article-title": "Nasal Irrigation in the COVID-19 Era", "first-page": "004", "journal-title": "IJCMCR", "key": "ref_15", "volume": "13", "year": "2021" }, { "article-title": "Hypertonic saline nasal irrigation and gargling as an inexpensive practical adjunctive weapon to combat asymptomatic SARS-CoV-2 infections. A case reports", "first-page": "1", "journal-title": "Trends Med.", "key": "ref_16", "volume": "20", "year": "2020" }, { "DOI": "10.1002/alr.22703", "article-title": "Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with COVID-19", "doi-asserted-by": "crossref", "first-page": "1325", "journal-title": "Int. Forum Allergy Rhinol.", "key": "ref_17", "volume": "10", "year": "2020" }, { "DOI": "10.1007/s12070-021-02749-9", "doi-asserted-by": "crossref", "key": "ref_18", "unstructured": "Yildiz, E., Koca, Y.S., Kuzu, S., Günebakan, Ç., Bucak, A., and Kahveci, O.K. (2021). Comparison of the Healing Effect of Nasal Saline Irrigation with Triamcinolone Acetonide Versus Nasal Saline Irrigation alone in COVID-19 Related Olfactory Dysfunction: A Randomized Controlled Study. Indian J. Otolaryngol. Head Neck Surg., 1–6." }, { "article-title": "Smell recovery in patients with COVID-19: An experience with nebulized nasal treatment", "first-page": "683", "journal-title": "J. Biol. Regul. Homeost. Agents", "key": "ref_19", "volume": "35", "year": "2021" }, { "article-title": "Viral shedding in symptomatic patients with mild COVID-19: An experience with nebulized nasal treatment", "first-page": "1155", "journal-title": "J. Biol. Regul. Homeost. Agents", "key": "ref_20", "volume": "35", "year": "2021" }, { "article-title": "Hypertonic saline with xylitol and hyaluronate may shorten the viral shedding duration in asymptomatic COVID-19 positive subjects: A pilot study", "first-page": "1151", "journal-title": "J. Biol. Regul. Homeost. Agents", "key": "ref_21", "volume": "35", "year": "2021" }, { "DOI": "10.1016/j.jhin.2021.10.019", "article-title": "Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2", "doi-asserted-by": "crossref", "first-page": "9", "journal-title": "J. Hosp. Infect.", "key": "ref_22", "volume": "120", "year": "2022" }, { "key": "ref_23", "unstructured": "(2022, August 16). NCT05458336. A Non-Randomized Controlled Clinical Trial on the Use of Saline Nasal Irrigations to Eradicate Localized Nasal Infection by SARS-CoV-2, Available online: https://clinicaltrials.gov/ct2/show/NCT05458336." }, { "DOI": "10.3389/fpubh.2021.652842", "article-title": "Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A systematic review and meta-analysis", "doi-asserted-by": "crossref", "first-page": "652842", "journal-title": "Front. Public Health", "key": "ref_24", "volume": "9", "year": "2021" }, { "article-title": "COVID-Q: Validation of the first COVID-19 questionnaire based on patient-rated symptom gravity", "first-page": "e14829", "journal-title": "Int. J. Clin. Pract.", "key": "ref_25", "volume": "75", "year": "2021" }, { "key": "ref_26", "unstructured": "University of British Columbia Clinical Significance Calculator, University of British Columbia. Available online: https://www.elcomprimido.com/FARHSD/DOC_CD_Curso_Palma_2006/calculadoras/UBC%20Clinical%20Significance%20Calculator.htm." }, { "key": "ref_27", "unstructured": "Peace, K.E. (1990). Statistical Issues in Drug Research and Development, Marcel Dekker." }, { "DOI": "10.1186/s13063-018-2989-5", "article-title": "Statistical analysis plan of a randomized controlled trial to compare a restrictive strategy to usual care for the effectiveness of cholecystectomy (SECURE trial)", "doi-asserted-by": "crossref", "first-page": "604", "journal-title": "Trials", "key": "ref_28", "volume": "19", "year": "2018" }, { "key": "ref_29", "unstructured": "United Stated Environmental Protection Agency (USEPA) (2022, November 07). About List N: Disinfectants for Corona-Virus (COVID-19), Available online: https://www.epa.gov/coronavirus/about-list-n-disinfectants-coronavirus-covid-19-0." }, { "DOI": "10.1007/s00228-021-03102-3", "article-title": "Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19", "doi-asserted-by": "crossref", "first-page": "1275", "journal-title": "Eur. J. Clin. Pharmacol.", "key": "ref_30", "volume": "77", "year": "2021" }, { "DOI": "10.1021/acsptsci.1c00080", "article-title": "Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells", "doi-asserted-by": "crossref", "first-page": "1514", "journal-title": "ACS Pharmacol. Trans. Sci.", "key": "ref_31", "volume": "4", "year": "2021" }, { "DOI": "10.3181/00379727-106-26352", "article-title": "Effect of several inorganic salts on the infectivity of Mengo virus", "doi-asserted-by": "crossref", "first-page": "402", "journal-title": "Proc. Soc. Exp. Biol. Med.", "key": "ref_32", "volume": "106", "year": "1961" }, { "DOI": "10.1038/ncomms6081", "article-title": "Ubiquitin-proteasome system controls ciliogenesis at the initial step of axoneme extension", "doi-asserted-by": "crossref", "first-page": "5081", "journal-title": "Nat. Commun.", "key": "ref_33", "volume": "5", "year": "2014" }, { "DOI": "10.1371/journal.pone.0240012", "doi-asserted-by": "crossref", "key": "ref_34", "unstructured": "Akgun, E., Tuzuner, M.B., Sahin, B., Kilercik, M., Kulah, C., Cakiroglu, H.N., Serteser, M., Unsal, I., and Baykal, A.T. (2020). Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients. PLoS ONE, 15." }, { "DOI": "10.1090/S0002-9904-1967-11798-1", "article-title": "Differentiable dynamical systems", "doi-asserted-by": "crossref", "first-page": "747", "journal-title": "Bull. Am. Math. Soc.", "key": "ref_35", "volume": "73", "year": "1967" }, { "DOI": "10.1177/154405910808701003", "article-title": "Inorganic chemistry of defensive peroxidases in the human oral cavity", "doi-asserted-by": "crossref", "first-page": "900", "journal-title": "J. Dent. Res.", "key": "ref_36", "volume": "87", "year": "2008" }, { "DOI": "10.1128/iai.51.1.49-53.1986", "article-title": "Antimicrobial factors in whole saliva of human infants", "doi-asserted-by": "crossref", "first-page": "49", "journal-title": "Infect. Immun.", "key": "ref_37", "volume": "51", "year": "1986" }, { "article-title": "N-chlorotaurine, a promising future candidate for topical therapy of fungal infections", "first-page": "161", "journal-title": "Mycopathologia", "key": "ref_38", "volume": "n183", "year": "2018" }, { "DOI": "10.21037/ajo-21-45", "article-title": "Xylitol nasal preparations in sinonasal disease: A literature review and meta-analysis", "doi-asserted-by": "crossref", "first-page": "8", "journal-title": "Aust. J. Otolaryngol.", "key": "ref_39", "volume": "5", "year": "2022" }, { "DOI": "10.1080/09546634.2017.1325310", "article-title": "Topical use of dexpanthenol: A 70th anniversary article", "doi-asserted-by": "crossref", "first-page": "766", "journal-title": "J. Dermatol. Treat.", "key": "ref_40", "volume": "28", "year": "2017" }, { "DOI": "10.1007/s00405-021-06644-5", "article-title": "A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: A new potential solution for upper respiratory tract hygiene", "doi-asserted-by": "crossref", "first-page": "3099", "journal-title": "Arch. Otorhinolaryngol.", "key": "ref_41", "volume": "278", "year": "2021" }, { "DOI": "10.1016/S1473-3099(20)30232-2", "article-title": "Viral dynamics in mild and severe cases of COVID-19", "doi-asserted-by": "crossref", "first-page": "656", "journal-title": "Lancet Infect. Dis.", "key": "ref_42", "volume": "20", "year": "2020" }, { "DOI": "10.1136/pgmj.2006.054767", "article-title": "Acute rhinosinusitis in adults: An update on current management", "doi-asserted-by": "crossref", "first-page": "402", "journal-title": "Postgrad. Med. J.", "key": "ref_43", "volume": "83", "year": "2007" }, { "key": "ref_44", "unstructured": "(2022, August 14). NHS England Updated UK Health Security Agency (UKHSA) Guidance–Isolation. Available online: https://www.england.nhs.uk/coronavirus/documents/updated-uk-health-security-agency-ukhsa-guidance-isolation/#Self%20isolation%20for%20NHS%20staff." }, { "key": "ref_45", "unstructured": "European Centre for Disease Prevention and Control (ECDC) (2022, August 14). Guidance on Quarantine of Close Contacts to COVID-19 Cases and Isolation of COVID-19 Cases, in the Current Epidemiological Situation, 7 January 2022. Available online: https://www.ecdc.europa.eu/en/covid-19/prevention-and-control/quarantine-and-isolation." }, { "DOI": "10.3390/v14081663", "doi-asserted-by": "crossref", "key": "ref_46", "unstructured": "Cegolon, L., Ronchese, F., Ricci, F., Negro, C., and Larese-Filon, F. (2022). SARS-CoV-2 Infection in Health Care Workers of Trieste (North-Eastern Italy), 1 October 2020–7 February 2022: Occupational Risk and the Impact of the Omicron Variant. Viruses, 14." }, { "DOI": "10.3390/v12040372", "doi-asserted-by": "crossref", "key": "ref_47", "unstructured": "Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., and Duan, G. (2020). Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 12." } ], "reference-count": 47, "references-count": 47, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/1999-4923/14/11/2502" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmaceutical Science" ], "subtitle": [], "title": "Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial", "type": "journal-article", "volume": "14" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit